In vivo reflectance confocal microscopy to monitor the response of lentigo maligna to imiquimod - 18/06/14
Abstract |
Background |
Imiquimod has been used for treating lentigo maligna (LM) in selected cases when surgery is not an appropriate option because of functional or aesthetic impairment. Reflectance confocal microscopy (RCM) is a noninvasive method that has not been validated for monitoring the treatment of LM with imiquimod.
Objective |
We sought to evaluate the use of in vivo RCM to accurately monitor the response of LM to nonsurgical treatment with topical imiquimod.
Methods |
Twenty patients with confirmed facial LM, not amenable to surgical treatment or radiation therapy, were included prospectively. Clinical evaluation was performed by dermoscopy, RCM, and histopathology. Patients applied imiquimod 5% for 8 weeks. The affected area was assessed using the previously described LM score on RCM, and target sample biopsies were performed to confirm or discard RCM findings.
Results |
Fifteen of the 20 patients (75%) presented histologic tumor clearance. Confocal microscopy identified 70% of these responders with no false-negative results, and when compared with histopathology, there was no significant difference in evaluating the response to imiquimod.
Limitations |
The impossibility of examining the entire lesion by means of histopathology is a limitation.
Conclusion |
In vivo RCM evaluation was useful in accurately monitoring the response of LM to nonsurgical treatment with topical imiquimod in patients when surgery is contraindicated.
Le texte complet de cet article est disponible en PDF.Key words : dermoscopy, imiquimod, lentigo maligna, melanoma, noninvasive diagnosis, nonsurgical treatment, reflectance confocal microscopy
Plan
| The research at the Melanoma Unit in Barcelona is partially funded by grants 09/1393 and 12/00840 from Fondo de Investigaciones Sanitarias, Spain; by the Centro de Investigación Biomédica en Red (CIBER) de Enfermedades Raras of the Instituto de Salud Carlos III, Spain, cofunded by “Fondo Europeo de Desarrollo Regional, Unión Europea, Una manera de hacer Europa”; by the Agència de Gestió d'Ajuts Universitaris i de Recerca (AGAUR) 2009 SGR 1337 of the Catalan Government, Spain; by the European Commission under the Sixth Framework Programme, Contract no. LSHC-CT-2006-018702 (GenoMEL); and by the National Cancer Institute of the US National Institutes of Health (CA83115). The sponsors had no role in the design and conduct of the study; in the collection, analysis, and interpretation of data; or in the preparation, review, or approval of the manuscript. |
|
| Conflicts of interest: None declared. |
Vol 71 - N° 1
P. 49-55 - juillet 2014 Retour au numéro
Article précédent
- Glomus tumors in individuals with neurofibromatosis type 1
- Monique G. Kumar, Ryan J. Emnett, Susan J. Bayliss, David H. Gutmann
- Diagnosis and treatment monitoring of toenail onychomycosis by reflectance confocal microscopy: Prospective cohort study in 58 patients
- Momen Pharaon, Martine Gari-Toussaint, Abdallah Khemis, Kevin Zorzi, Laurent Petit, Philippe Martel, Robert Baran, Jean Paul Ortonne, Thierry Passeron, Jean Philippe Lacour, Philippe Bahadoran
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?